NCT05060406Unknown3 期
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 入组人数
- 448
- 试验地点
- 1
- 主要终点
- Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine
研究概览
简要总结
A multicenter, randomized, double-blind, placebo-controlled phase III clinical study will be conducted to evaluate the efficacy and safety of LY06006 in the treatment of postmenopausal women with osteoporosis at high risk for fracture, as well as an exploratory population pharmacokinetic analysis of LY06006.
详细描述
It is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial.
Primary Objective:
To evaluate the efficacy of LY06006 in the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Secondary Objectives:
To evaluate the safety of LY06006. To evaluate the immunogenicity of LY06006. Population pharmacokinetic analysis of LY06006.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
盲法说明
Double (Participant, Investigator)
入排标准
- 年龄范围
- 50 Years 至 85 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Postmenopausal woman, ages ≥50 to ≤85 years.≥3 years postmenopausal, which can be≥3 years of spontaneous amenorrhea or ≥3 years post-surgical bilateral oophorectomy. If < 60 years of age and had hysterectomy but ovarian retention, require follicle stimulating hormone (FSH) levels ≥40U/L.
排除标准
- •Low BMD (BMD absolute value consistent with a T-score≤-2.5 and >-4.0 at either the lumbar spine or total hip). The BMD equivalents by T-score thresholds for each DXA scanner manufacturer are provided below.
- •Have at least one of the following risk factors:
- •history of fragility fracture
- •parental history of hip fracture
- •low body weight (BMI≤19kg/m2)
- •elderly (age≥65y)
- •current smoker
- •Voluntarily signed written informed consent
- •Exclusion criteria
- •Bone/metabolic disease:
- •Any metabolic bone disease, e.g., osteomalacia or osteogenesis imperfecta,
- •Paget's disease
- •Cushing's disease
- •Hyperprolactinemia
- •Hypopituitarism
- •Current hyperparathyroidism or hypoparathyroidism by medical record.
- •Current hyperthyroidism or hypothyroidism (allowed if having normal hormone level on thyroid hormone replacement therapy or 5.5μIU/mL<thyroid-stimulating hormone (TSH) level≤10.0μIU/mL, but the serum thyroxine (T4) is within the normal range.
- •Malabsorption syndrome or any gastrointestinal disorders associated with malabsorption, for example Crohn's Disease and chronic pancreatitis.
- •Hypocalcemia or hypercalcemia, or serum albumin corrected blood calcium level is not within the normal range of the laboratory;
- •Vitamin D deficiency: 25 hydroxy vitamin D (25OHD) level <20 ng/mL. (allowed 200,000 units of vitamin D2 injection (trade name: Futai®) once during the screening period, and re-test the 25OHD level once. Those with 25OHD level ≥20 ng/mL can be included
- •Others such as rheumatoid arthritis, gout, multiple myeloma and so on.
- •Subjects with a history of greater than 2 vertebral fractures.
- •Malignancy within the 5 years before enrollment (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical or breast ductal carcinoma in situ).
- •Severe renal disease, creatinine clearance <30mL/min
- •Liver or biliary diseases:
- •Cirrhosis of the liver;
- •Biliary tract abnormalities (except asymptomatic gallstones);
- •Positive Hepatitis C virus (HCV) antibody;
- •Positive hepatitis B surface antigen (HBsAg) test with the peripheral blood hepatitis B virus deoxyribonucleic acid (HBV DNA) titer test ≥1×103 copies/mL (if positive HBsAg with the peripheral blood HBV DNA titer test <1× 103 copies/mL, the subject is eligible for selection if the investigator believes that the subject is in a stable phase of chronic hepatitis B and will not increase the risk of the subject,;
- •Alkaline phosphatase <lower limit of normal (LLN); alkaline phosphatase or total bilirubin ≥ 1.5 times the upper limit of normal (ULN); serum aspartate aminotransferase (AST) ≥ 2.0×ULN; serum alanine Acid aminotransferase (ALT) ≥2.0×ULN;
- •Oral/Dental Diseases
- •Prior history or current evidence of osteomyelitis or osteonecrosis of the jaw.
- •Active dental or jaw condition which requires oral surgery.
- •Planned invasive dental procedure.
- •Non-healed dental or oral surgery.
- •DXA measurements:
- •Less than two lumbar vertebrae evaluable for DXA measurements.
- •Height, weight, or girth that could preclude accurate DXA measurements.
- •Administration of the following medications:
- •RANKL inhibitor, fluoride or strontium salt or intravenous bisphosphonate within the past 5 years;
- •Oral bisphosphonates, allowed if patients had the following conditions :
- •Cumulative use> 3 months but <3 years: ≥ 6 months before the last medication was taken from the screening visit;
- •Cumulative use ≤3 months;
- •parathyroid hormone (PTH) or parathyroid hormone analogs (PTHa) within 6 weeks before screening, such as teriparatide; anabolic hormones or testosterone; glucocorticoids (equivalent to> 5 mg/day strength Pine> 10 days); systemic hormone replacement therapy; selective estrogen receptor modulators (SERMs), such as raloxifene; tibolone; calcitonin; active vitamin D and its analogs; other bone active drugs including anticonvulsants (except benzodiazepines) and heparin; long-term systemic use of ketoconazole, androgens, corticotropin, cinacalcet, aluminum, lithium, protease inhibitors, methotrexate, Gonadotropin releasing hormone agonist;
- •Positive human immunodeficiency virus (HIV) antibody.
- •Self-reported alcohol or drug abuse [defined as drinking an average of 14 units or more of alcoholic beverages per week in the 3 months before screening (1 unit = 350 mL of beer, or 45 mL of liquor, or 150 mL of wine)]
- •Known allergy to the treatment drugs used in the research protocol, including allergy to the test drugs
- •Have received any other experimental drug treatment or prior participation in another interventional clinical trial within 3 months before screening
- •Other severe acute or chronic diseases, psychiatric disorder or abnormal laboratory tests, etc., in the opinion of the investigator, not suitable for participating in this research.
研究组 & 干预措施
LY06006 60mg
Experimental
injection
Interventions:
Drug: LY06006 Injection； Dietary Supplement: Elemental Calcium； Dietary Supplement: Vitamin D
干预措施: LY06006 (Drug)
Placebo
Placebo Comparator
injection
Interventions:
Drug: Placebo； Dietary Supplement: Elemental Calcium； Dietary Supplement: Vitamin D
干预措施: LY06006 (Drug)
结局指标
主要结局
Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine
时间窗: Baseline and Month 12
Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine at Month 12
次要结局
- Percent Change in Serum Procollagen Type I N Propeptideserum (s-PINP) From Baseline(Baseline, Month 1, Month 6 and Month 12)
- Percent Changes in total hip BMD(Baseline,Month 6 and Month 12)
- Percent Changes in femoral neck BMD(Baseline,Month 6 and Month 12)
- Percent Change in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) From Baseline(Baseline, Month 1, Month 6 and Month 12)
- Percent Changes in trochanteric BMD(Baseline,Month 6 and Month 12)
- Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine(Baseline and Month 6)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1GlioblastomaNCT03776071Denovo Biopharma LLC260
已完成
3 期
A Study of AK0529 in Chinese Infants Hospitalized With RSVRespiratory Syncytial Virus InfectionsNCT04231968Shanghai Ark Biopharmaceutical Co., Ltd.311
已完成
3 期
Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLCStage II-III Non-small Cell Lung CancerNCT04158440Shanghai Junshi Bioscience Co., Ltd.501
进行中（未招募）
3 期
Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue VaccineDengueNCT02406729Butantan Institute16,935
已完成
3 期
A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing SpondylitisAnkylosing SpondylitisNCT06378697Akeso510